Published in PLoS One on September 23, 2013
Current and emerging Legionella diagnostics for laboratory and outbreak investigations. Clin Microbiol Rev (2015) 1.41
Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One (2014) 1.32
Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 1.12
The cell envelope glycoconjugates of Mycobacterium tuberculosis. Crit Rev Biochem Mol Biol (2014) 1.06
New target prediction and visualization tools incorporating open source molecular fingerprints for TB Mobile 2.0. J Cheminform (2014) 1.03
Genome Analysis of the First Extensively Drug-Resistant (XDR) Mycobacterium tuberculosis in Malaysia Provides Insights into the Genetic Basis of Its Biology and Drug Resistance. PLoS One (2015) 0.93
New agents for the treatment of drug-resistant Mycobacterium tuberculosis. Adv Drug Deliv Rev (2016) 0.90
Rapid Chagas disease drug target discovery using directed evolution in drug-sensitive yeast. ACS Chem Biol (2016) 0.88
The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. ACS Infect Dis (2016) 0.86
The future for early-stage tuberculosis drug discovery. Future Microbiol (2015) 0.84
Whole-genome sequencing targets drug-resistant bacterial infections. Hum Genomics (2015) 0.84
Release of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discovery. PLoS One (2015) 0.81
Inhibiting Mycobacterium tuberculosis within and without. Philos Trans R Soc Lond B Biol Sci (2016) 0.80
Integrated Modeling of Gene Regulatory and Metabolic Networks in Mycobacterium tuberculosis. PLoS Comput Biol (2015) 0.80
Structure-Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis. ACS Infect Dis (2016) 0.80
Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target. PLoS One (2014) 0.80
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. Antimicrob Agents Chemother (2016) 0.80
The mycobacterial cell envelope-lipids. Cold Spring Harb Perspect Med (2014) 0.79
A novel antimycobacterial compound acts as an intracellular iron chelator. Antimicrob Agents Chemother (2015) 0.79
Mycobacterial phylogenomics: an enhanced method for gene turnover analysis reveals uneven levels of gene gain and loss among species and gene families. Genome Biol Evol (2014) 0.79
Chemical biology applied to the study of bacterial pathogens. Infect Immun (2014) 0.79
Revealing bacterial targets of growth inhibitors encoded by bacteriophage T7. Proc Natl Acad Sci U S A (2014) 0.78
Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase. Antimicrob Agents Chemother (2016) 0.78
Bioautography with TLC-MS/NMR for Rapid Discovery of Anti-tuberculosis Lead Compounds from Natural Sources. ACS Infect Dis (2016) 0.78
Network analysis identifies Rv0324 and Rv0880 as regulators of bedaquiline tolerance in Mycobacterium tuberculosis. Nat Microbiol (2016) 0.78
Structures of EccB1 and EccD1 from the core complex of the mycobacterial ESX-1 type VII secretion system. BMC Struct Biol (2016) 0.77
Using a Label Free Quantitative Proteomics Approach to Identify Changes in Protein Abundance in Multidrug-Resistant Mycobacterium tuberculosis. Indian J Microbiol (2015) 0.76
The EXIT Strategy: an Approach for Identifying Bacterial Proteins Exported during Host Infection. MBio (2017) 0.76
Deletion of cyp125 Confers Increased Sensitivity to Azoles in Mycobacterium tuberculosis. PLoS One (2015) 0.76
Learning from the past for TB drug discovery in the future. Drug Discov Today (2016) 0.76
Host-Directed Therapies for Tuberculosis. Cold Spring Harb Perspect Med (2015) 0.76
Brachyspira hyodysenteriae and B. pilosicoli Proteins Recognized by Sera of Challenged Pigs. Front Microbiol (2017) 0.75
Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression. Sci Rep (2017) 0.75
Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research. Clin Infect Dis (2016) 0.75
In silico identification and characterization of a hypothetical protein of Mycobacterium tuberculosis EAI5 as a potential virulent factor. Bioinformation (2016) 0.75
Imidazoles Induce Reactive Oxygen Species in Mycobacterium tuberculosis Which Is Not Associated with Cell Death. ACS Omega (2017) 0.75
Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome. Trends Pharmacol Sci (2017) 0.75
Translating genomics research into control of tuberculosis: lessons learned and future prospects. Genome Biol (2014) 0.75
Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery. Antimicrob Agents Chemother (2016) 0.75
Caught between two proteins: a mycobacterial inhibitor challenges the mold. Mol Microbiol (2016) 0.75
A genome-wide structure-based survey of nucleotide binding proteins in M. tuberculosis. Sci Rep (2017) 0.75
In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13. Cell (2017) 0.75
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev (2001) 36.00
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science (2004) 13.04
Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature (2000) 11.48
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother (1997) 9.16
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin. Proc Natl Acad Sci U S A (2001) 7.65
M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) (2004) 4.38
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog (2011) 4.10
Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science (1998) 4.08
The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One (2008) 3.87
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Recombineering in Mycobacterium tuberculosis. Nat Methods (2006) 3.18
Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol (2002) 2.91
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol (2007) 2.83
The ATP binding cassette (ABC) transport systems of Mycobacterium tuberculosis. FEMS Microbiol Rev (2000) 2.71
High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis (Edinb) (2009) 2.58
Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2000) 2.50
Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem (2000) 2.43
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol (2012) 2.40
Dynamic thiolation-thioesterase structure of a non-ribosomal peptide synthetase. Nature (2008) 2.39
Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol (2010) 2.36
Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon. J Bacteriol (2006) 2.33
Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis. ChemMedChem (2013) 2.20
Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A (2009) 2.10
The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J Biol Chem (2002) 2.04
Efflux pumps as antimicrobial resistance mechanisms. Ann Med (2007) 1.99
Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog (2009) 1.96
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol (2005) 1.94
Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis (Edinb) (2009) 1.94
4-thiazolidinone--a biologically active scaffold. Eur J Med Chem (2007) 1.91
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci U S A (2011) 1.71
Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2004) 1.64
Characterization of a Mycobacterium tuberculosis ESX-3 conditional mutant: essentiality and rescue by iron and zinc. J Bacteriol (2009) 1.62
The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol Med (2002) 1.58
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob Agents Chemother (2005) 1.53
The role of IS6110 in the evolution of Mycobacterium tuberculosis. Tuberculosis (Edinb) (2007) 1.53
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother (2011) 1.51
Nanomolar inhibitors of Staphylococcus aureus methionyl tRNA synthetase with potent antibacterial activity against gram-positive pathogens. J Med Chem (2002) 1.42
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth. Antimicrob Agents Chemother (2009) 1.38
Relationship of protein structure of isoleucyl-tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl-tRNA synthetase. J Biol Chem (1994) 1.35
Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase (NDH-2). J Biol Chem (2006) 1.35
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system. Tuberculosis (Edinb) (2008) 1.24
Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. Nat Chem Biol (2013) 1.20
Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother (2007) 1.19
Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis. ChemMedChem (2009) 1.19
The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis. J Biol Chem (2009) 1.14
Role of dimerization in yeast aspartyl-tRNA synthetase and importance of the class II invariant proline. Proc Natl Acad Sci U S A (1993) 1.12
Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl Environ Microbiol (2011) 1.11
Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother (2005) 1.09
Stimulation of transposition of the Mycobacterium tuberculosis insertion sequence IS6110 by exposure to a microaerobic environment. Mol Microbiol (1999) 1.08
An intermediate step in the recognition of tRNA(Asp) by aspartyl-tRNA synthetase. J Mol Biol (2000) 1.07
Selective intracellular accumulation of the major metabolite issued from the activation of the prodrug ethionamide in mycobacteria. J Antimicrob Chemother (2006) 0.99
Measuring minimum inhibitory concentrations in mycobacteria. Methods Mol Biol (2009) 0.98
Contribution of the Rv2333c efflux pump (the Stp protein) from Mycobacterium tuberculosis to intrinsic antibiotic resistance in Mycobacterium bovis BCG. J Antimicrob Chemother (2007) 0.94
Inhibitors of the salicylate synthase (MbtI) from Mycobacterium tuberculosis discovered by high-throughput screening. ChemMedChem (2010) 0.89
Inhibition studies of Mycobacterium tuberculosis salicylate synthase (MbtI). ChemMedChem (2010) 0.88
Peptide deformylase inhibitors as potent antimycobacterial agents. Antimicrob Agents Chemother (2006) 0.87
Isolation of mycobacterium species genomic DNA. Methods Mol Biol (2009) 0.86
RecA-independent single-stranded DNA oligonucleotide-mediated mutagenesis. F1000 Biol Rep (2010) 0.82
Structural studies of human purine nucleoside phosphorylase: towards a new specific empirical scoring function. Arch Biochem Biophys (2008) 0.80
Synthesis, characterization and antifungal evaluation of 5-substituted-4-amino-1,2,4-triazole-3-thioesters. Molecules (2011) 0.77
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol (2003) 16.82
Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A (2003) 9.15
Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med (2003) 7.99
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet (2012) 6.78
A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature (2004) 6.29
Recent developments in the PHENIX software for automated crystallographic structure determination. J Synchrotron Radiat (2003) 6.28
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
A genome-scale analysis for identification of genes required for growth or survival of Haemophilus influenzae. Proc Natl Acad Sci U S A (2002) 5.70
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol (2003) 5.68
Automated structure solution with the PHENIX suite. Methods Mol Biol (2008) 5.65
Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation. J Infect Dis (2002) 5.15
Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun (2008) 4.93
Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A (2008) 4.92
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem (2004) 4.75
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (2008) 4.74
Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis. Mol Microbiol (2004) 4.62
Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. Proc Natl Acad Sci U S A (2005) 4.43
Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest (2008) 4.41
Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev Microbiol (2005) 4.38
Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet (2011) 4.19
Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science (2011) 4.13
High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism. PLoS Pathog (2011) 4.10
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2005) 3.97
The enduring hypoxic response of Mycobacterium tuberculosis. PLoS One (2008) 3.87
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One (2009) 3.68
Drosophila RNAi screen reveals CD36 family member required for mycobacterial infection. Science (2005) 3.49
Age and the epidemiology and pathogenesis of tuberculosis. Lancet (2010) 3.37
DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell (2003) 3.36
CsoR is a novel Mycobacterium tuberculosis copper-sensing transcriptional regulator. Nat Chem Biol (2006) 3.30
Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 3.29
Genome-wide RNAi screen for host factors required for intracellular bacterial infection. Science (2005) 3.28
The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol (2003) 3.15
Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol (2004) 3.12
Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun (2003) 3.01
The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe (2008) 2.98
Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis. Nat Rev Microbiol (2008) 2.97
Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance. Infect Immun (2005) 2.89
Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A (2005) 2.84
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Two sensor kinases contribute to the hypoxic response of Mycobacterium tuberculosis. J Biol Chem (2004) 2.71
Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem (2003) 2.63
The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A (2003) 2.60
Dynamic population changes in Mycobacterium tuberculosis during acquisition and fixation of drug resistance in patients. J Infect Dis (2012) 2.53
Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J Infect Dis (2005) 2.50
A replication clock for Mycobacterium tuberculosis. Nat Med (2009) 2.49
Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect Immun (2004) 2.47
The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro. Mol Microbiol (2008) 2.44
The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated. J Bacteriol (2007) 2.42
SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 2.41
Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis of Mycobacterium tuberculosis. J Med Chem (2006) 2.37
Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol (2010) 2.36
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med (2006) 2.35
Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat Immunol (2012) 2.34
Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) (2004) 2.33
NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog (2009) 2.31
Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr Pharm Des (2004) 2.30
Characterization of mycobacterial virulence genes through genetic interaction mapping. Proc Natl Acad Sci U S A (2006) 2.29
Construction of a mariner-based transposon for epitope-tagging and genomic targeting. Gene (2002) 2.15
Proteasomal protein degradation in Mycobacteria is dependent upon a prokaryotic ubiquitin-like protein. J Biol Chem (2008) 2.12
Mycobacterial Esx-3 is required for mycobactin-mediated iron acquisition. Proc Natl Acad Sci U S A (2009) 2.10
Mycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanisms. J Immunol (2004) 2.08
Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med (2011) 2.06
The Mycobacterium tuberculosis regulatory network and hypoxia. Nature (2013) 2.04
Metabolic regulation of mycobacterial growth and antibiotic sensitivity. PLoS Biol (2011) 2.04
Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev (2008) 2.01
Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol (2002) 1.99
The role of MmpL8 in sulfatide biogenesis and virulence of Mycobacterium tuberculosis. J Biol Chem (2004) 1.99
Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell (2013) 1.96
Systematic genetic nomenclature for type VII secretion systems. PLoS Pathog (2009) 1.96
The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol (2005) 1.94
Prospects for new antitubercular drugs. Curr Opin Microbiol (2004) 1.94
Genomic analysis identifies targets of convergent positive selection in drug-resistant Mycobacterium tuberculosis. Nat Genet (2013) 1.93
Twin RNA polymerase-associated proteins control virulence gene expression in Francisella tularensis. PLoS Pathog (2007) 1.92
The Mycobacterium tuberculosis protein serine/threonine kinase PknG is linked to cellular glutamate/glutamine levels and is important for growth in vivo. Mol Microbiol (2004) 1.89
Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J Bacteriol (2002) 1.86
Global assessment of genomic regions required for growth in Mycobacterium tuberculosis. PLoS Pathog (2012) 1.85
Crystal structure of Mycobacterium tuberculosis SecA, a preprotein translocating ATPase. Proc Natl Acad Sci U S A (2003) 1.83
igr Genes and Mycobacterium tuberculosis cholesterol metabolism. J Bacteriol (2009) 1.82